Seagen (SGEN) to Present New Data for ADCETRIS with Immunotherapy Combination in Hodgkin Lymphoma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Updated Phase 2 data for ADCETRIS in combination with nivolumab in early and advanced stage classical Hodgkin lymphoma to be presented in oral session –– First preclinical data for investigational antibody-drug conjugate SGN-35C to be presented –BOTHELL, Wash. (BUSINESS WIRE) #ASH23 Seagen Inc. (NASDAQ: SGEN) t.
16.10.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines . Seite 1
- Long-term follow-up data for PADCEV® with KEYTRUDA® in advanced bladder cancer to be featured as oral presentation –
- Updated Phase 1 data on first-in-class integrin beta-6. | April 26, 2023
- Data presentations demonstrate continued potential of PADCEV® (enfortumab vedotin-ejfv) in multiple types of urothelial cancer Patient-reported outcomes underscore Seagen’s commitment to addressing patients’ needs and quality of life -BOTHELL, Wash. (BUSINESS WIRE) Seagen Inc. (Nasdaq: SGEN) today announced t.